---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-002209"
form_type: "8-K/A"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2023-01-23T23:59:59+00:00"
generated_at: "2026-06-20T11:38:13.353973+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# INVO gets Nasdaq extension until May 22, 2023 to regain compliance with equity rule

## Summary
- Received Nasdaq deficiency notice on Nov 23, 2022 for stockholders' equity of $1.287M vs $2.5M minimum.
- Submitted compliance plan; Nasdaq granted extension until May 22, 2023 on Jan 18, 2023.
- Must file a publicly available report describing the transaction that enables compliance.
- If not compliant by June 30, 2023 filing, Nasdaq may delist; company can appeal to Hearings Panel.

## SEC filing metadata
- accession: 0001493152-23-002209
- form_type: 8-K/A
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2023-01-23T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000149315223002209/0001493152-23-002209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000149315223002209/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-002209
- JSON: https://secwatch.observer/filing/0001493152-23-002209.json
- Plain text: https://secwatch.observer/filing/0001493152-23-002209.txt

## Key facts
- Listing & Compliance Notices
  INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: (the “Stockholders’ Equity Requirement). In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company reported stockholders’ equity of $1,287,224, which is below the Stockholders’ Equity Requirement for continued listing. Additionally, as of the date of the Notice, the Company did not meet either of the alternative Nasdaq
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315223002209/0001493152-23-002209-index.htm
- Listing & Compliance Notices
  INVO Fertility, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5550(b)
  source text: January 18, 2023 letter from Nasdaq granting an extension of time to regain compliance with Nasdaq Listing Rule 5550(b) until May 22, 2023. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 23, 2022, INVO Bioscience, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315223002209/0001493152-23-002209-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.